TrialESMO open2023

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.

L C Villaruz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.